Pharmacists in Seattle, Washington


1645 Pharmacists found in Seattle
female pharmacist

Yujun Luo, PHARMD


Pharmacist
720 8th Ave S, Seattle, WA 98104
206-788-3770    

female pharmacist

Yun H Russ, R.PH. BCPP


Pharmacist - Psychiatric
1660 S Columbian Way, Vapshcs S-116-mhc, Seattle, WA 98108
206-277-4500     206-764-2572

female pharmacist

Yun Young Hwang


Pharmacist
747 Broadway, Seattle, WA 98122
206-386-6000    



male pharmacist

Yusuf Rashid, R.PH.


Pharmacist
7527 33rd Ave Ne, Seattle, WA 98115
206-581-6178    

female pharmacist

Yvodney C Tyrrel


Pharmacist
7300 Roosevelt Way Ne, Seattle, WA 98115
206-524-1649    

female pharmacist

Yvonne Marie Wake, RPH


Pharmacist
9800 4th Ave Ne, Seattle, WA 98115
206-302-1337     206-302-1270

female pharmacist

Yvonne Mark, PHARMD


Pharmacist - Clinician (PhC)/ Clinical Pharmacy Specialist
1959 Ne Pacific St, Box 354735, Seattle, WA 98195
206-598-5579     206-598-2717

female pharmacist

Yvonne D Bates


Pharmacist
200 15th Ave E, Seattle, WA 98112
206-326-2990    

female pharmacist

Zahra Noamouz, PHARMD


Pharmacist
4025 Delridge Way Sw, Seattle, WA 98106
206-736-2626    

male pharmacist

Zakary Cerminara


Pharmacist - Oncology
825 Eastlake Ave E, Seattle, WA 98109
206-606-1040    

male pharmacist

Mr. Zereit Haileselassie, RPH


Pharmacist
1001 Madison St Ste 150, Seattle, WA 98104
800-619-7610     800-619-7611

male pharmacist

Mr. Zerihun Shenkute, RPH


Pharmacist
325 9th Ave, Seattle, WA 98104
206-744-3219    

male pharmacist

Zsolt Hepp


Pharmacist
5409 15th Ave Nw, Seattle, WA 98107
206-781-0056    


Type of Pharmacists:
Psychiatric Pharmacist: A licensed pharmacist who has demonstrated specialized knowledge and skill in optimizing care of patients with psychiatric illness by assessing and monitoring patients, recognizing drug-induced problems, and recommending appropriate treatment plans.
Oncology Pharmacist: A licensed pharmacist who has demonstrated specialized knowledge and skill in developing, recommending, implementing, monitoring, and modifying pharmacotherapeutic plans to optimize outcomes in patients with malignant diseases.